Akeso clinical trial pipeline

5 trials changed in the last 30 days: 1 stopped, 2 with notable changes, 2 with minor changes only.

1. Stopped

   AK104 for Recurrent or Metastatic Vulvar Cancer

   Trial terminated

   Also in this update: Primary completion date changed from estimate of Dec 15, 2025 to May 31, 2026

   Akeso·Phase 2· NCT05932212· Registry history of NCT05932212 on ClinicalTrials.gov (opens the registry)

   Sep 28, 2026

2. Notable

   AK157D1 for Injection in Advanced Solid Tumors

   Recruitment opened

   Also in this update: Start date changed from estimate of Sep 21, 2026 to Sep 30, 2026

   Akeso·Phase 1· NCT07847281· Registry history of NCT07847281 on ClinicalTrials.gov (opens the registry)

   Oct 13, 2026

3. Notable

   G/GEJ · Cadonilimab Combined With Chemotherapy vs Chemotherapy in…G/GEJ · Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment · HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma

   Recruitment opened

   Akeso·Phase 3· NCT07700979· Registry history of NCT07700979 on ClinicalTrials.gov (opens the registry)

   Sep 29, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.